Keynote Trials for Ovarian Cancer

As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.

Below are trials currently being conducted in ovarian cancer, evaluating the investigational study drug, pembrolizumab (MK-3475).

Active Clinical Trials

The cancer types listed below currently have active trial listings on Click on a study name to be directed to that trial's information, or call 1-888-577-8839 to find a study site near you for the trial you are interested in.

keynote trial image

Efficacy and Safety Study of Pembrolizumab in Women With Advanced Recurrent Ovarian Cancer

This study will assess the efficacy and safety of pembrolizumab (MK-3475) in women with advanced ovarian cancer who have demonstrated recurrent disease following the front line platinum-based treatment and debulking surgery and received up to 5 lines of treatment for recurrent ovarian cancer (ROC) per local standard of care. Participants will receive pembrolizumab every 3 weeks (Q3W) for up to 2 years.

more about the study

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.